Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB222 vs bevacizumab plus chemotherapy in advanced non-squamous NSCLC
CTR20171085Phase 3Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GB222 in non-small cell lung cancer (NSCLC), sponsored by Jacobio Pharmaceuticals. Started Dec 2017; status: active.
02
Drugs
GB222
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20171085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171085.